Robust Potency Assays: From MoA-Based Design to Lifecycle Management
10 Dec, 2026 | 15:00 CET
Join us as we explore the key considerations for developing and maintaining effective potency assays throughout the product lifecycle.
Speakers:
Frances Reichert PhD - Technical Specialist Biologics, Eurofins BioPharma Product Testing Munich
Paul Morrissey PhD – Senior Manager, Molecular and Cell Biology Department, Eurofins BioPharma Product Testing Ireland
Bioassays are a critical component of biopharmaceutical development, providing a measure of biological activity that supports product characterisation, release testing, stability studies and regulatory submissions. As increasingly complex biologics progress through development, establishing robust and scientifically relevant potency assays presents both technical and regulatory challenges.
Join us as we explore the key considerations for developing and maintaining effective potency assays throughout the product lifecycle. From selecting a mechanism of action (MoA)-based strategy through assay development, qualification, validation and long-term lifecycle management, our experts will share practical approaches for generating meaningful biological activity data while ensuring regulatory compliance and assay robustness.
What you will learn
- Selecting the right potency assay based on the mechanism of action
- Assay development and optimisation
- Qualification and validation strategies
- Critical reagent lifecycle management
Whether you are developing potency assays for early-stage products or managing validated methods for commercial programmes, this webinar will provide practical insights to help strengthen assay performance, support regulatory expectations and ensure long-term assay reliability.
📅 Date: 10 Nov, 2026 | 15:00 CEST